Work

Phase I/II study of MEDI-551, a humanized monoclonal antibody targeting CD19, in subjects with relapsed or refractory advanced B-cell malignancies.

Year: 2012

Type: conference-abstract

Source: Journal of Clinical Oncology

DOI: 10.1200/jco.2012.30.15_suppl.8065

Authors: Trishna Goswami, Andres Forero, Mehdi Hamadani, Anne Sonet, Gregor Verhoef, Michelle A. Fanale, Celeste M. Bello, Wenmei Huang, Bruce D. Cheson

Institutions: University of Alabama at Birmingham, West Virginia University, West Virginia University Hospitals, CHU Dinant Godinne UCL Namur, Universitair Ziekenhuis Leuven, The University of Texas MD Anderson Cancer Center, Moffitt Cancer Center, Georgetown University Medical Center

Language: English

Topic: Lymphoma Diagnosis and Treatment

Subfield: Pathology and Forensic Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W2523970392

Cites:

Cited by: 4

Related to: 10